Stem cells have the potential for unlimited self-renewal and differentiation, making them highly promising for both basic research and clinical applications. The advancements in gene editing technologies, particularly CRISPR and TALEN, enable precise molecular modifications at the genomic level. This not only expands the range of diseases that can be targeted by stem cell therapy, but also enhances the safety aspect of treatment. 
YuanVore Medicine combines iPSCs with genomic approaches to establish three major technological platforms, providing new avenues for precision regenerative medicine.